Advertisement

Breast Cancer

  • Simona Ben-Haim
  • Vineet Prakash
Chapter

Abstract

Breast cancer is the most common cancer in women in the Western world and in most Western countries and the second leading cause of cancer-related death in women with an age-adjusted incidence of 117.7 women per year in 2004.1 The National Cancer Institute estimates 178,480 women will be diagnosed with breast cancer and 40,640 women will die of breast cancer in 2007 in the United States, most of them of progressive metastatic disease.

Keywords

Breast Cancer Positron Emission Tomography Standard Uptake Value National Comprehensive Cancer Network National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors are thankful to Prof. Peter J. Ell for critically reviewing this chapter.

References

  1. 1.
    Ries LAG, Melbert D, Krapacho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2004. Bethesda, MD:National Cancer Institute, http://seer.cancer.gov/csr/19752004/, posted to the SEER web site 2007.
  2. 2.
  3. 3.
    Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:1601–1602.CrossRefPubMedGoogle Scholar
  4. 4.
    Avril N, Adler LP. F-18 Fluorodeoxyglucos positron emission tomography imaging for primary breast cancer and loco-regional staging. PET Clinics 2006;1:1–14.CrossRefGoogle Scholar
  5. 5.
    Eubank WB. Diagnosis of recurrent and metastatic disease using F-18 fluorodeoxyglucose-positron emission tomography. PET Clinics 2006;1:15–24.CrossRefGoogle Scholar
  6. 6.
    Quon A, Gambhir SS. FDG-PET and beyond: Molecular breast cancer imaging. J Clin Oncol 2005;23:1664–1673.CrossRefPubMedGoogle Scholar
  7. 7.
    Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006;79:32–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Scheidhauer K, Walter C, Seedmann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 2004;31(Suppl. 1):S70–S79.CrossRefPubMedGoogle Scholar
  9. 9.
    Wahl RL, Siegel BA, Coleman R, Gatsonis CG. A prospective multicentre study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277–285.CrossRefPubMedGoogle Scholar
  10. 10.
    Aarsvold JN, Alzaraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. Semin Nucl Med 2005;35:116–128.CrossRefPubMedGoogle Scholar
  11. 11.
    Iagaru A, Masamed R, Keesara H, Conti PS. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 2007;21:33–38.CrossRefPubMedGoogle Scholar
  12. 12.
    Tafra L. Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 2007;14:3–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84–99.CrossRefPubMedGoogle Scholar
  14. 14.
    Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and skeletal metastases. Semin Nucl Med 2005;35:135–142.CrossRefPubMedGoogle Scholar
  15. 15.
    Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: Sequential [18F] Fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of skeletal metastases in breast cancer. J Clin Oncol 2007;25:3440–3447.CrossRefPubMedGoogle Scholar
  16. 16.
    Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T,Nishimura T. Pitfalls of FDG-PET for the diagnosis of osteoblastic skeletal metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253–1258.CrossRefPubMedGoogle Scholar
  17. 17.
    Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 2004;31(Suppl.1): S135–S142.CrossRefPubMedGoogle Scholar
  18. 18.
    Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254–262.CrossRefPubMedGoogle Scholar
  19. 19.
    Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005;11:204–209.CrossRefPubMedGoogle Scholar
  20. 20.
    Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105–112.CrossRefPubMedGoogle Scholar
  21. 21.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Romper M, Ruiz G, Montz R, Carreras JL. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002;46:113–121.PubMedGoogle Scholar
  22. 22.
    Eubank WB, Mankoff DA, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seumour M, Livingston R. Impact of [18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. Am J Roentgenol 2004;183:479–486.Google Scholar
  23. 23.
    Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratio O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imag Biol 2005;7:369–376.CrossRefGoogle Scholar
  24. 24.
    Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545–2551.CrossRefPubMedGoogle Scholar
  25. 25.
    Belli P, Constantini M, Romani M, Marano P, Pastore G. Magnetic resonance imaging in breast cancer recurrence. Breast Cancer Res Treat 2002;73:223–235.CrossRefPubMedGoogle Scholar
  26. 26.
    Goerres GW, Michel SCA, Fehr MK, Kaim AH, Steinert HC, Seifert B, von Schulthess GK, Kubik-Hoch RA. Follow-up of women with breast cancer: Comparison between MRI and FDG PET. Eur Radiol 2003;13:1635–1644.CrossRefPubMedGoogle Scholar
  27. 27.
    Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and breast for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224–239.PubMedGoogle Scholar
  28. 28.
    Biersack HJ, Bender H, Palmedo H.FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 2004;31(Suppl. 1):S112–S117.CrossRefPubMedGoogle Scholar
  29. 29.
    Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002;43:325–329.PubMedGoogle Scholar
  30. 30.
    Schwartz JD, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144–1150.Google Scholar
  31. 31.
    Berriolo-Riedinger A, Touzery C, Riedinger J-M, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915–1924.CrossRefPubMedGoogle Scholar
  32. 32.
    Heron DE, Beriwal S, Avril N. FDG-PET and PET/CT in radiation therapy simulation and management of patients who have primary and recurrent breast cancer. PET Clinics. 2006;1:39–49.CrossRefGoogle Scholar
  33. 33.
    Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, Keil K, Komaki R, Larson SM, Mankoff DA, Rozenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN task force report: Positron emission tomography (PET/Computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5 (Suppl 1): S1–S22. www/nccn.org/professionals/physician_gls/f_guidelines.asp PubMedGoogle Scholar
  34. 34.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N , Einhorn LH, Suh WW, Samson D, Delbeke D,Gorman M, Shields AF. Recommendations for the Use of FDG (fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) Positron emission tomography in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  35. 35.
    Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET:Histopathologic comparison. Radiology 2004;230:417–422.CrossRefPubMedGoogle Scholar
  36. 36.
    Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, Inbar M, Metser U. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006;33:541–552.CrossRefPubMedGoogle Scholar
  37. 37.
    Pickel H, Reich O. Ovarian metastases of breast cancer. CME Journal of Gynecologic Oncology 2004;9:129–132.Google Scholar
  38. 38.
    Hann LE, Lui DM, Shi W, Bach AM, Selland D-L, Castiel M. Adnexal masses in women with breast cancer: US findings with clinical and histopathologic correlation. Radiology 2000;216:242–247.PubMedGoogle Scholar
  39. 39.
    Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, Bomanji JB, Ell PJ. The impact of 18F-FDG PET/CT in patients with hepatic metastases. Eur J Nucl Med Mol Imaging 2007;34:1906–1914.CrossRefPubMedGoogle Scholar
  40. 40.
    Turken O, NarIn Y, DemIrbas S, Onde ME, Sayan O, KandemIr EG, Yaylac IM, Ozturk A. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003;5:R110–R113.CrossRefPubMedGoogle Scholar
  41. 41.
    Agarwal DP, Soni TP, Sharma OP, Sharma S. Synchronous malignancies of breast and thyroid gland: A case report and review of literature. J Cancer Res Ther 2007;3:172–173.CrossRefPubMedGoogle Scholar
  42. 42.
    Hathaway PB, MAnkoff DA, MAravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, Cortese AA, Hayes CE, Moe RE. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer:Preliminary experience. Radiology 1999;210:807–814.PubMedGoogle Scholar
  43. 43.
    Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496–507.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Institute of Nuclear MedicineUniversity College London Hospital NHS TrustLondonUK

Personalised recommendations